Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
Earnings Data
Report Date
Oct 29, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.85Last Year’s EPS
-0.91Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in uniQure's clinical pipeline, especially with AMT-130 for Huntington's disease, and a strong financial position. However, the company faced challenges with decreased revenue and trial recruitment issues in epilepsy. Overall, the highlights outweigh the lowlights, suggesting a positive outlook.Company Guidance -
Q3 2025
Advancement of AMT-130 for Huntington's Disease
AMT-130 has received breakthrough therapy designation from the FDA, indicating its potential as the first disease-modifying therapy for Huntington's disease. The company achieved regulatory alignment with the FDA on the statistical analysis plan and CMC requirements for a planned BLA submission in early 2026.
Encouraging Data for AMT-260 in Epilepsy
The first patient treated with AMT-260 for mesial temporal lobe epilepsy experienced a 92% reduction in seizure frequency over five months with no significant adverse events.
Strong Financial Position
Cash, cash equivalents, and investment securities totaled $377 million as of June 30, 2025, providing a solid foundation to fund operations into the second half of 2027.
Progress in Broader Clinical Pipeline
Advancements were made in clinical programs for AMT-191 for Fabry disease and AMT-162 for SOD1-ALS, with initial data expected in September 2025 and first half of 2026, respectively.
QURE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
QURE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 29, 2025 | $14.98 | $13.68 | -8.68% |
May 09, 2025 | $12.25 | $12.79 | +4.41% |
Feb 27, 2025 | $11.67 | $12.07 | +3.43% |
Nov 05, 2024 | $5.56 | $6.06 | +8.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does uniQure N.V. (QURE) report earnings?
uniQure N.V. (QURE) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).
What is uniQure N.V. (QURE) earnings time?
uniQure N.V. (QURE) earnings time is at Oct 29, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is QURE EPS forecast?
QURE EPS forecast for the fiscal quarter 2025 (Q3) is -0.85.